GNMSF News and Press, Genmab A/S Dkk From 05/04/23

2023-05-04 04:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund gained 3.75% (Institutional Shares) during the first q...

2023-04-25 02:01:13 ET Summary To identify the most promising pharmaceutical companies with a market capitalization of more than $1 billion, we use an eight-step selection process, which will be discussed below. The following two articles will feature our list of the top 10 pharma...

Company Announcement C OPENHAGEN , Denmark; April 24 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB ) announced today its decision to file a request for review of the award dismissing its claims in the second arbitration arising under i...

Company Announcement COPENHAGEN , Denmark; April 21 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB ) announced today an award in the second arbitration arising under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab...

Company Announcement Net sales of DARZALEX ® in the first quarter of 202 3 totaled USD 2,264 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; April 18 , 2...

Media Release COPENHAGEN, Denmark; April 1 7 , 2023 Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies Disc...

Genmab A/S (GMAB) Q4 2022 Results Conference Call February 22, 2023 12:00 PM ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Judith Klimovsky - Chief Development Officer Anthony Mancini - Ch...

Company Announcement Repurchase of up to 2 2 0,000 shares H onoring commitments under our Restricted Stock Unit program Completion expected on March 31 , 2023 COPENHAGEN , Denmark; February 22, 20 2 3 ...

Company Announcement COPENHAGEN , Denmark; February 22, 2023 – Genmab A/S ( Nasdaq: GMAB ) announced today the publication of its Annual Report for 2022. Below is a summary of business progress in 2022, financial performance for the year an...

Company Announcement Net sales of DARZALEX ® in 2022 totaled USD 7, 977 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc . (Janssen) COPENHAGEN, Denmark; January 24, 2023 – Genmab A/S...